Cargando…

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1

Detalles Bibliográficos
Autores principales:	Fiskus, Warren, Daver, Naval, Boettcher, Steffen, Mill, Christopher P., Sasaki, Koji, Birdwell, Christine E., Davis, John A., Das, Kaberi, Takahashi, Koichi, Kadia, Tapan M., DiNardo, Courtney D., Burrows, Francis, Loghavi, Sanam, Khoury, Joseph D., Ebert, Benjamin L., Bhalla, Kapil N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9613474/ https://www.ncbi.nlm.nih.gov/pubmed/36151141 http://dx.doi.org/10.1038/s41375-022-01707-w

Ejemplares similares

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
por: Fiskus, Warren, et al.
Publicado: (2023)

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
por: Fiskus, Warren, et al.
Publicado: (2022)

Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax
por: Rausch, Johanna, et al.
Publicado: (2023)

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1
por: Mill, Christopher P., et al.
Publicado: (2023)

PB1761: PRECLINICAL EVALUATION OF THE MENIN INHIBITOR ZIFTOMENIB IN PRIMARY AML SPECIMENS
por: Stevens, Brett, et al.
Publicado: (2023)

EVI1 dysregulation: impact on biology and therapy of myeloid malignancies
por: Birdwell, Christine, et al.
Publicado: (2021)

Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
por: Fiskus, Warren, et al.
Publicado: (2022)

A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1
por: Numata, Masashi, et al.
Publicado: (2023)

P504: UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
por: Fathi, Amir, et al.
Publicado: (2023)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target
por: Brzezinka, Krzysztof, et al.
Publicado: (2020)

Development of an orally bioavailable selective inhibitor of the menin-MLL
por: Zhong, Hai-Jing, et al.
Publicado: (2022)

A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin–MLL Inhibition
por: Soto-Feliciano, Yadira M., et al.
Publicado: (2023)

Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin
por: Svoboda, Laurie K., et al.
Publicado: (2016)

The MLL–Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML
por: Rasouli, Milad, et al.
Publicado: (2023)

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
por: Issa, Ghayas C., et al.
Publicado: (2023)

The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
por: Heikamp, Emily B., et al.
Publicado: (2022)

Multi-omics analyses of MEN1 missense mutations identify disruption of menin–MLL and menin–JunD interactions as critical requirements for molecular pathogenicity
por: Dreijerink, Koen M. A., et al.
Publicado: (2022)

LBODP106 Multi-omics Analyses Of MEN1 Missense Mutations Identify Disruption Of Menin-MLL And Menin-JunD Interactions As Critical Requirements For Molecular Pathogenicity
por: Dreijerink, Koen Marie Anton, et al.
Publicado: (2022)

IKAROS and MENIN Coordinate Therapeutically Actionable Leukaemogenic Gene Expression in MLL-r Acute Myeloid Leukaemia
por: Aubrey, Brandon J., et al.
Publicado: (2022)

Menin–MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and Cancers
por: Shi, Qing, et al.
Publicado: (2023)

Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
por: Ye, Jing, et al.
Publicado: (2019)

Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection
por: Abbas, Hussein A, et al.
Publicado: (2019)

Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series
por: Alotaibi, Ahmad S., et al.
Publicado: (2020)

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia
por: Tashakori, Mehrnoosh, et al.
Publicado: (2022)

Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells
por: Fiskus, Warren, et al.
Publicado: (2021)

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2021)

Resistance to targeted therapies: delving into FLT3 and IDH
por: Desikan, Sai Prasad, et al.
Publicado: (2022)

Menin and Menin-Associated Proteins Coregulate Cancer Energy Metabolism
por: Chou, Chih-Wei, et al.
Publicado: (2020)

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study
por: Reville, Patrick K., et al.
Publicado: (2021)

High-Affinity Small-Molecule Inhibitors of the Menin-Mixed Lineage Leukemia (MLL) Interaction Closely Mimic a Natural Protein–Protein Interaction
por: He, Shihan, et al.
Publicado: (2014)

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

The role of menin in bone pathology
por: Gorbacheva, Anna, et al.
Publicado: (2022)

Acute myeloid leukemia: current progress and future directions
por: Kantarjian, Hagop, et al.
Publicado: (2021)

FBP1 Is an Interacting Partner of Menin
por: Zaman, Shadia, et al.
Publicado: (2014)

Menin: Expanding and dichotomous roles in cancer
por: Katona, Bryson W., et al.
Publicado: (2019)

BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells
por: Saenz, Dyana T., et al.
Publicado: (2016)

P496: PHENOTYPIC SUBTYPES OF LEUKEMIC TRANSFORMATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2023)

Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
por: Loghavi, Sanam, et al.
Publicado: (2014)

PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Zeidan, Amer M, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ibllavuqah0to90nse06k99r8m